EHRA Premium Access

Impact of high-power and very high-power short-duration radiofrequency ablation on procedure characteristics and first-pass isolation during pulmonary vein isolation

Topic: Rhythm Control, Catheter Ablation

Congress Session

About the speaker

Doctor Zoltan Sallo

Semmelweis University Heart and Vascular Center, Budapest (Hungary)
0 follower

6 more presentations in this session

Persistent phrenic nerve palsy after atrial fibrillation ablation: follow-up data from the Netherlands Heart Registration

Speaker: Doctor J. de Jong (Amsterdam, NL)

Thumbnail

Pulsed field ablation as the first choice regarding oesophageal safety for atrial fibrillation ablation?

Speaker: Doctor J. Katic (Split, HR)

Thumbnail

Areas of minimal generator impedance drop during the index atrial fibrillation ablation correlate with pulmonary vein reconnection sites despite adopting the CLOSE protocol

Speaker: Doctor A. Malaweera (London, GB)

Thumbnail

Comparison of left atrial lesion size and troponin release of two novel single shot devices for pulmonary vein isolation: pulsed field ablation vs. multi-electrode radiofrequency balloon

Speaker: Doctor M. Lemoine (Hamburg, DE)

Thumbnail

The triangle correlation among the impact on serum S100B protein release, incidence of the silent cerebral ischemic phenomena and pulsed field ablation for patients with atrial fibrillation.

Speaker: Professor K. Chun (Frankfurt am Main, DE)

Thumbnail

Access the full session

Moderated ePosters - News on AF ablation

Speakers: Doctor Z. Sallo, Doctor J. de Jong, Doctor J. Katic, Doctor A. Malaweera, Doctor M. Lemoine...
Thumbnail

About the event

Image

EHRA 2022

3 April - 5 April 2022

Sessions Presentations

Related content

EHRA Premium Access

Atrial high-rate episodes in patients with devices without a history of atrial fibrillation

3 April 2022

Open Access

A curated selection of highlights

24 October 2021

ESC Premium Access

The ESC journey and future directions.

22 October 2021

This platform is supported by

logo Novo Nordisk